Claims
- 1. A compound of Formula 1 or Formula 2:
- 2. The compound of claim 1 which is a compound of Formula 1.
- 3. The compound of claim 1 or 2 where m is 0.
- 4. The compound of any one of claims 1 through 3 where n is 1.
- 5. The compound of any one of claims 1 through 4 where at least one of X, Y, R1, R2, R3, R4, and R5 is not hydrogen.
- 6. The compound of any one of claims 1 through 5 where X is —NR6R7.
- 7. The compound of any one of claims 1 through 6 where Y is —CO2R6 or —CO2NR6R7.
- 8. The compound of any one of claims 1 through 7 where Z is —CO2R6 or —CO2NR6R7.
- 9. The compound of claim 1 which is a compound of Formula I wherein m is 0, n is 1, R1, R2, R3 and R4 are all hydrogen, both Y and Z are —COOH and X is —NR6R7 in which both R6 and R7 are methyl.
- 10. A pharmaceutical composition comprising:
(a) a therapeutically effective amount of a compound of any one of claims 1 through 8; and (b) a pharmaceutically acceptable excipient.
- 11. A method of treating an animal having a disease or injury capable of treatment by administration of a GPE analog or peptidomimetic, comprising administration to that animal of a therapeutically effective amount of a compound of any one of claims 1 through 8.
- 12. The method of claim 11 where the disease is Alzheimer's disease.
- 13. The method of claim 11 where the disease is multiple sclerosis.
- 14. The method of claim 11 where the disease is Parkinson's disease.
- 15. The method of claim 11 where the disease is peripheral neuropathy.
- 16. The method of claim 15 where the disease is Huntington's disease.
- 17. The method of claim 11 where the disease is type I diabetes.
- 18. The method of claim 11 where the disease is type II diabetes.
- 19. The method of claim 11 where the injury is stroke.
- 20. The method of claim 11 where the injury is traumatic brain injury.
- 21. The method of claim 11 where the injury is hypoxic brain injury.
- 22. The method of claim 11 where the injury is ischemic brain injury.
- 23. The method of claim 11 where the injury is perinatal asphyxia.
- 24. The method of any one of claims 11 through 23 where at least one other anti-apoptotic or neuroprotective agent is administered.
- 25. The method of claim 24 where the at least one other anti-apoptotic or neuroprotective agent is selected from selected from growth factors and associated derivatives (insulin-like growth factor-I [IGF-I], insulin-like growth factor-II [IGF-II], transforming growth factor-β1, activin, growth hormone, nerve growth factor, growth hormone binding protein, IGF-binding proteins [especially IGFBP-3], basic fibroblast growth factor, acidic fibroblast growth factor, the hst/Kfgk gene product, FGF-3, FGF-4, FGF-6, keratinocyte growth factor, androgen-induced growth factor, int-2, fibroblast growth factor homologous factor-1 (FHF-1), FHF-2, FHF-3 and FHF-4, keratinocyte growth factor 2, glial-activating factor, FGF-10 and FGF-16, ciliary neurotrophic factor, brain derived growth factor, neurotrophin 3, neurotrophin 4, bone morphogenetic protein 2 [BMP-2], glial-cell line derived neurotrophic factor, activity-dependant neurotrophic factor, cytokine leukaemia inhibiting factor, oncostatin M, interleukin), α-, β-, γ-, or consensus interferon, TNF-α, clomethiazole; kynurenic acid, Semax, tacrolimus, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol, adrenocorticotropin-(4-9) analog [ORG 2766], dizolcipine [MK-801], selegiline, glutamate antagonists such as NPS1506, GV1505260, MK-801, GV150526, AMPA antagonists such as 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline (NBQX), LY303070 and LY300164, and anti-inflammatory agents directed against the addressin MAdCAM-1 and/or its integrin α4 receptors (α4β1 and α4β7), such as anti-MAdCAM-1mAb MECA-367 (ATCC accession no. HB-9478).
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims the priority under 35 USC 119(e) of U.S. Provisional Application No. 60/293,853, filed May 24, 2001, which is incorporated by reference into this application.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60293853 |
May 2001 |
US |